On March 19, 2024, Robert Schumm, a director of Senseonics Holdings, Inc. who was designated to serve as a director of the Company by PHC Holdings Corporation (PHC), notified the Board of Directors of the Company of his resignation from the Board effective March 19, 2024. Mr. Schumm?s resignation follows PHC designating Brian Hansen to oversee the Ascensia Diabetes Care Continuous Glucose Monitoring (CGM) business, while Mr. Schumm continues to oversee its Blood Glucose Monitoring business, and is not due to any disagreements with the Company or its management on any matter relating to the Company?s operations, policies, or practices. On March 20, 2024, the Board appointed Brian Hansen to serve as a director of the Company.

Mr. Hansen will serve as a Class III director whose term will expire at the 2025 annual meeting of stockholders. Mr. Hansen was designated by PHC to serve as a director of the Company pursuant to that certain Investor Rights Agreement (the PHC IRA), dated August 9, 2020, by and between the Company and PHC. Brian Hansen, age 56, has served as Ascensia?s President of CGM since February 2024.

Mr. Hansen is an executive with over 30 years of commercial experience in the medical device, life sciences and diagnostic industries. Prior to joining Ascensia, he served as EVP and CCO at Tandem Diabetes Care since January 2016. Prior to that, he held key leadership roles at Adaptive Biotechnologies, Novartis, Gen-Probe and Fisher Scientific.

Mr. Hansen has a BSBA from the University of Missouri and an MBA from San Diego State University.